New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc

Nov 4, 2026

Strategic Roche Diagnostics Partnership, New Biomarker Findings and Expanding Clinical Research Could Help Transform Patient Selection for Non-Small Cell Lung Cancer Treatment, While Genprex, Inc. (N A S D A Q: GNPX) Advances Additional Opportunities in Small Cell Lung Cancer and Diabetes Gene Therapy.

AUSTIN, Texas - Nov. 4, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is generating renewed attention across the biotechnology sector with another important research development involving its lead investigational gene therapy, REQORSA®. The company announced November 4 that new research has identified TROP2 expression as a potential predictive biomarker for response to REQORSA, adding another important dimension to its developing precision-medicine strategy for lung cancer.

The announcement is particularly encouraging because researchers identified a relationship between TROP2 expression and treatment sensitivity across multiple preclinical models of non-small cell lung cancer (NSCLC). The findings were further supported by an analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial evaluating REQORSA.

For Genprex, this represents an important opportunity to build upon its existing clinical research and investigate how biomarker testing could help identify patients most likely to benefit from treatment. The company is working toward a more personalized approach to cancer therapy, an area receiving increasing attention throughout the oncology industry.

The new research is scheduled to be presented November 18–20 at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

New TROP2 Findings Add Momentum to REQORSA

The November 4 announcement highlights the potential importance of TROP2 expression in determining sensitivity to REQORSA.

Researchers found that low TROP2 expression was consistently associated with primary resistance to REQORSA across multiple preclinical NSCLC models. Analysis of pretreatment tumor biopsies from clinical-trial participants provided additional support for these observations.

The findings are important because biomarkers may help researchers better understand why certain patients respond differently to cancer treatments.

If additional research confirms these relationships, TROP2 testing could become an important component of patient selection for future REQORSA clinical studies.

Genprex is also investigating PTEN, another important biomarker associated with treatment response. Together, these research efforts demonstrate the company's interest in combining innovative gene therapy with more targeted approaches to cancer treatment.

Roche Diagnostics Collaboration: A Significant Strategic Relationship

One of Genprex's most important developments this year is its collaboration with Roche Diagnostics, announced August 3.

The partnership focuses on validating biomarker assays designed to help identify appropriate patients for Genprex's NSCLC clinical program.

Roche brings extensive diagnostic expertise to the collaboration, while Genprex contributes its developing gene therapy platform and growing body of biomarker research.

The initial work centers on two important biomarkers:
  • TROP2: Being investigated for its potential ability to identify patients more likely to respond to REQORSA.
  • PTEN: A tumor-suppressor protein whose expression has also demonstrated an association with treatment response in previous research.

Roche Diagnostics will conduct assay validation using its TROP2 antibody. Genprex anticipated completion of these studies around the end of 2026, with potential integration into its NSCLC clinical program following successful validation.

This collaboration is especially noteworthy because it connects Genprex with an established global diagnostics organization while advancing a more sophisticated patient-selection strategy.

The ultimate objective is to better identify patients who may benefit from REQORSA and potentially improve the precision of future clinical studies.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology strategy is REQORSA, also known as quaratusugene ozeplasmid.

The investigational gene therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 is frequently reduced or absent in several forms of lung cancer. REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression.

Genprex is investigating REQORSA through its Acclaim clinical development program.

Acclaim-1 evaluates REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3 evaluates REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs represent important components of the company's longer-term oncology ambitions. The programs have received FDA Fast Track designations, and the small cell lung cancer program has also received Orphan Drug Designation.

These designations provide important regulatory development pathways as Genprex continues its clinical research.

TUSC2 Research Creates Additional Scientific Interest

Genprex is also expanding its scientific investigation of TUSC2 through its sponsored research collaboration with Meharry Medical College.

On November 4, research titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for presentation at the Gerontological Society of America's 2026 Annual Scientific Meeting.

The research explores TUSC2's relationship with mitochondrial biology, cellular resilience and biological processes associated with aging.

This follows an October 21 peer-reviewed publication examining TUSC2's role in maintaining cellular function during brain aging.

These developments add another dimension to the company's scientific platform by examining the broader biological functions of the gene central to REQORSA.

While additional research is necessary to establish any potential therapeutic applications beyond oncology, the work demonstrates continued scientific interest in TUSC2.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond cancer, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The company's approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

On August 18, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This represents an important development as the company works toward preparing the program for future clinical studies.

Having separate development programs targeting cancer and diabetes gives Genprex multiple areas of potential therapeutic opportunity.

Looking Ahead: Important Catalysts for $GNPX Investors

Genprex has several meaningful milestones approaching:
  • November 18–20: Presentation of new TROP2 biomarker research in Barcelona.
  • Late 2026: Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim oncology clinical programs.
  • Additional TUSC2 research and scientific collaboration developments.
  • Continued manufacturing scale-up for the diabetes gene therapy program.

Genprex Is Building an Intriguing Gene Therapy Story

Genprex brings together several important areas of biotechnology innovation: precision lung cancer treatment, gene therapy, biomarker-guided patient selection and diabetes research.

The latest TROP2 findings add another important piece to the REQORSA development story, while the Roche Diagnostics collaboration provides a valuable strategic relationship as the company works toward more personalized cancer treatment approaches.

With additional scientific presentations ahead, continued clinical development and a second therapeutic program targeting diabetes, Genprex has multiple opportunities to demonstrate further progress.

For investors following emerging biotechnology companies, GNPX presents an evolving story centered on innovative science, strategic collaboration and the pursuit of potentially important new treatment options. The coming months could be especially meaningful as Genprex works to translate its expanding research foundation into further clinical development milestones.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc | More news from this source

Press release distribution by PRLog
MORE NEWS
Portland spark China fans’ fury with cryptic Yang Hansen post, risk Macau NBA windfall
Nov 16, 2026
Portland spark China fans’ fury with cryptic Yang Hansen post, risk Macau NBA windfall

A routine NBA Cup victory for Portland Trail Blazers should not have sparked fury among China’s passionate fans, but the belief the club snubbed Yang Hansen on social media afterwards was more than they could take. And it could prove costly, with the Oregon franchise tipped to play in the NBA China Games in Macau next year. Some fans have already suggested it would be tough to sell tickets without the local hero on show. The slightly predictable backlash followed an Instagram post including 20...

James McDonald ‘can’t wait’ to ride Little Paradise for the first time in Jockey Club Mile
Nov 16, 2026
James McDonald ‘can’t wait’ to ride Little Paradise for the first time in Jockey Club Mile

Superstar jockey James McDonald is convinced Little Paradise will prove himself a major Group One Hong Kong Mile contender when he makes his stable debut for Danny Shum Chap-shing in Sunday’s Group Two BOCHK Private Wealth Jockey Club Mile. Returning to Hong Kong for the first time since champion Romantic Warrior’s final start in May, McDonald jumped at the chance to ride Little Paradise when approached by Shum and has been impressed with his recent work for his new trainer. Owner Ko Kam-piu...

Ukraine’s Svitolina heads to war-torn home front after WTA Finals loss
Nov 16, 2026
Ukraine’s Svitolina heads to war-torn home front after WTA Finals loss

Elina Svitolina will return to Ukraine next week, pledging to continue supporting her country through donations, her foundation and ‌the platform she has built in tennis. The Ukrainian lost 7-5 6-3 to Russia’s Mirra Andreeva in Sunday’s championship match of the season-ending championship WTA Finals, but said the support she receives from home remains a powerful source of motivation during Russia’s war in Ukraine. “It’s been almost five years. I’ve always been supportive of the army and the...

Rory McIlroy wins record-equalling eighth Race to Dubai title on DP World Tour
Nov 16, 2026
Rory McIlroy wins record-equalling eighth Race to Dubai title on DP World Tour

Rory McIlroy won his eighth Race to Dubai title to tie the record of Scotland’s Colin Montgomerie after a dramatic final round of the season-ending US$10 million DP World Tour Championship on Sunday. The tournament itself was a runaway win for England’s Tyrrell Hatton (66) but all eyes were on the fascinating battle between McIlroy and Spain’s Eugenio Chacarra, playing a group behind, for the previously named “Order of Merit” award. It all came down to the 18th hole, where McIlroy made a...

FURIA defend their BLAST Premier Rivals Hong Kong crown in front of raucous AsiaWorld-Arena
Nov 15, 2026
FURIA defend their BLAST Premier Rivals Hong Kong crown in front of raucous AsiaWorld-Arena

FURIA continued the remarkable retirement tour for their captain and Counter-Strike legend Gabriel “FalleN” Toledo by defending their BLAST Premier Rivals Hong Kong crown with a 3-0 sweep of Spirit at the AsiaWorld-Arena on Sunday. As they did 12 months ago, FURIA ran riot in the city’s premier esports tournament, winning all four of their matches and proving dominant when it mattered most in the final. It has been a difficult year in the main for Brazilian-majority team FURIA, with their...

Youth Olympic Games: refugee athletes proud after overcoming adversity to compete for glory
Nov 15, 2026
Youth Olympic Games: refugee athletes proud after overcoming adversity to compete for glory

Lourence Numukiza, a 16-year-old athlete from Democratic Republic of Congo, has gone from being a war refugee to earning a prized berth at the Youth Olympic Games in Senegal. After a tough childhood spent in the Kakuma refugee camp in Kenya, the teenager said her path to Dakar was simple: “I trained hard, I competed hard and I was able to win.” She came in with two goals. Firstly, “I want to get a medal”, she said. That did not quite materialise but the other aim is still in focus as she looks...

Ethiopians boss Hong Kong-Zhuhai-Macau Bridge race, as local ace battles injury and stress
Nov 15, 2026
Ethiopians boss Hong Kong-Zhuhai-Macau Bridge race, as local ace battles injury and stress

Addisu Gobena targeted world and Olympic glory after obliterating an elite field to crown his breakout year with victory in the Bank of China Hong Kong-Zhuhai-Macau Bridge Half Marathon on Sunday. The 22-year-old’s Ethiopian compatriot Wede Kefale claimed the women’s title in what has become Hong Kong’s premium distance race only three years after a debut beset by troubles. Emerging from a “lonely and stressful” period in her career, Virginia Lo Ying-chiu was the first city woman home, with...

Hong Kong Island Coastal Trail Challenge attracts record number to explore scenic routes
Nov 15, 2026
Hong Kong Island Coastal Trail Challenge attracts record number to explore scenic routes

Residents and tourists can participate in a challenge starting on Monday to walk or run around Hong Kong Island’s 62-kilometre (38.5-mile) coastline in stages, collecting landmark pins and learning about the environment along the way. Now in its seventh year, the Hong Kong Island Coastal Trail Challenge has already attracted a record number of more than 1,200 participants this year and is split into a competitive racing division and an entry-level leisure category aimed at casual walkers and...

Japan earn small measure of World Cup revenge with Brazil defeat in Singapore
Nov 14, 2026
Japan earn small measure of World Cup revenge with Brazil defeat in Singapore

Japan and Brazil played out a five-goal thriller in front of nearly 40,000 fans at Singapore’s National Stadium on Saturday, with the Samurai Blue gaining some small measure of revenge for their painful World Cup defeat with a 3-2 win. The clash, both teams’ first friendly of this month’s international window, was the second of four matches in the inaugural Mizuho Blue Challenge – The Kallang Football Series, which also features the home team and Paraguay. The large turnout was a testament to...

Manchester United only considered Mauricio Pochettino to revive fortunes of troubled club
Nov 14, 2026
Manchester United only considered Mauricio Pochettino to revive fortunes of troubled club

From the moment Manchester United executives were made aware of Mauricio Pochettino’s availability, he stood alone – the only candidate as the troubled club set about hiring a new coach. With results tanking and the 20-time English champions languishing in the Premier League relegation zone, something had to be done. Who could revive the fortunes of the once dominant force after more than a decade of decline? In the end it came down to a choice of one. Unfortunately for the US men’s national...

Dirt race abandoned as delighted Matthew Poon brings up 300th Hong Kong win
Nov 14, 2026
Dirt race abandoned as delighted Matthew Poon brings up 300th Hong Kong win

There was dirt drama at Sha Tin on Saturday with the middle of three races on the surface abandoned due to safety concerns from the jockeys following 55mm of overnight rain. The downpour was sustained overnight and it was evident in the Class Five Panashop Handicap (1,650m), which was won by a mud-splattered Hailtothevictors and Jerry Chau Chun-lok for trainer David Eustace. The field finished in wide intervals, with nine lengths splitting first to eighth, a further 14 lengths back to the...

Pierre Ng’s sprint switch pays off with Johannes Brahms an upset Panasonic Cup winner
Nov 14, 2026
Pierre Ng’s sprint switch pays off with Johannes Brahms an upset Panasonic Cup winner

Championship-leading trainer Pierre Ng Pang-chi’s move to switch Johannes Brahms to sprinting paid dividends when the Irish import caused an upset at $34.75 in Saturday’s Class Two Panasonic Cup (1,200m) at Sha Tin. Third in the Classic Cup (1,800m) and sixth in the Hong Kong Derby (2,000m) in 2024, the Siyouni gelding lost form last season and bled from both nostrils in April, prompting Ng to give him an extended break. He returned with two solid but unspectacular runs over 1,000m and 1,200m...

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

SukanKini focuses on the nation’s favorite sports and local leagues and the rivalry between our teams with other players across South East Asia and even all over the world.